A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2016
At a glance
- Drugs Vortioxetine (Primary)
- Indications Generalised anxiety disorder
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 15 May 2009 Actual patient number (457) added as reported by ClinicalTrials.gov.
- 15 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2008 Planned end date changed from 1 Aug 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.